Novo Nordisk launched Awiqli, its weekly basal insulin injection, in India. The rollout targets a market with some of the world’s highest diabetes rates, supporting incremental revenue opportunity for Novo as it expands access beyond existing geographies.
Novo Nordisk launched Awiqli, its weekly basal insulin injection, in India. The rollout targets a market with some of the world’s highest diabetes rates, supporting incremental revenue opportunity for Novo as it expands access beyond existing geographies.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
